Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes

Background/Objectives: Drug development for complex diseases such as NAFLD is often lengthy and expensive. Drug repurposing, the process of finding new therapeutic uses for existing drugs, presents a promising alternative to traditional approaches. This study aims to identify potential repurposed dr...

Full description

Saved in:
Bibliographic Details
Main Authors: Md. Altaf-Ul-Amin, Ahmad Kamal Nasution, Rumman Mahfujul Islam, Pei Gao, Naoaki Ono, Shigehiko Kanaya
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Metabolites
Subjects:
Online Access:https://www.mdpi.com/2218-1989/15/4/255
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850144337618272256
author Md. Altaf-Ul-Amin
Ahmad Kamal Nasution
Rumman Mahfujul Islam
Pei Gao
Naoaki Ono
Shigehiko Kanaya
author_facet Md. Altaf-Ul-Amin
Ahmad Kamal Nasution
Rumman Mahfujul Islam
Pei Gao
Naoaki Ono
Shigehiko Kanaya
author_sort Md. Altaf-Ul-Amin
collection DOAJ
description Background/Objectives: Drug development for complex diseases such as NAFLD is often lengthy and expensive. Drug repurposing, the process of finding new therapeutic uses for existing drugs, presents a promising alternative to traditional approaches. This study aims to identify potential repurposed drugs for NAFLD by leveraging disease–disease relationships and drug–target data from the BioSNAP database. Methods: A bipartite network was constructed between drugs and their target genes, followed by the application of the BiClusO bi-clustering algorithm to identify high-density clusters. Clusters with significant associations with NAFLD risk genes were considered to predict potential drug candidates. Another set of candidates was determined based on disease similarity. Results: A novel ranking methodology was developed to evaluate and prioritize these candidates, supported by a comprehensive literature review of their effectiveness in NAFLD treatment. Conclusions: This research demonstrates the potential of drug repurposing to accelerate the development of therapies for NAFLD, offering valuable insights into novel treatment strategies for complex diseases.
format Article
id doaj-art-fd558d18a7464eb4a840877bbfd69288
institution OA Journals
issn 2218-1989
language English
publishDate 2025-04-01
publisher MDPI AG
record_format Article
series Metabolites
spelling doaj-art-fd558d18a7464eb4a840877bbfd692882025-08-20T02:28:24ZengMDPI AGMetabolites2218-19892025-04-0115425510.3390/metabo15040255Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and GenesMd. Altaf-Ul-Amin0Ahmad Kamal Nasution1Rumman Mahfujul Islam2Pei Gao3Naoaki Ono4Shigehiko Kanaya5Computational Systems Biology Lab, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, JapanComputational Systems Biology Lab, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, JapanComputational Systems Biology Lab, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, JapanComputational Systems Biology Lab, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, JapanComputational Systems Biology Lab, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, JapanComputational Systems Biology Lab, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, JapanBackground/Objectives: Drug development for complex diseases such as NAFLD is often lengthy and expensive. Drug repurposing, the process of finding new therapeutic uses for existing drugs, presents a promising alternative to traditional approaches. This study aims to identify potential repurposed drugs for NAFLD by leveraging disease–disease relationships and drug–target data from the BioSNAP database. Methods: A bipartite network was constructed between drugs and their target genes, followed by the application of the BiClusO bi-clustering algorithm to identify high-density clusters. Clusters with significant associations with NAFLD risk genes were considered to predict potential drug candidates. Another set of candidates was determined based on disease similarity. Results: A novel ranking methodology was developed to evaluate and prioritize these candidates, supported by a comprehensive literature review of their effectiveness in NAFLD treatment. Conclusions: This research demonstrates the potential of drug repurposing to accelerate the development of therapies for NAFLD, offering valuable insights into novel treatment strategies for complex diseases.https://www.mdpi.com/2218-1989/15/4/255BiClusO algorithmdisease similaritydrug repurposingnetwork analysisnon-alcoholic fatty liver disease (NAFLD)
spellingShingle Md. Altaf-Ul-Amin
Ahmad Kamal Nasution
Rumman Mahfujul Islam
Pei Gao
Naoaki Ono
Shigehiko Kanaya
Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes
Metabolites
BiClusO algorithm
disease similarity
drug repurposing
network analysis
non-alcoholic fatty liver disease (NAFLD)
title Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes
title_full Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes
title_fullStr Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes
title_full_unstemmed Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes
title_short Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes
title_sort drug repurposing for non alcoholic fatty liver disease by analyzing networks among drugs diseases and genes
topic BiClusO algorithm
disease similarity
drug repurposing
network analysis
non-alcoholic fatty liver disease (NAFLD)
url https://www.mdpi.com/2218-1989/15/4/255
work_keys_str_mv AT mdaltafulamin drugrepurposingfornonalcoholicfattyliverdiseasebyanalyzingnetworksamongdrugsdiseasesandgenes
AT ahmadkamalnasution drugrepurposingfornonalcoholicfattyliverdiseasebyanalyzingnetworksamongdrugsdiseasesandgenes
AT rummanmahfujulislam drugrepurposingfornonalcoholicfattyliverdiseasebyanalyzingnetworksamongdrugsdiseasesandgenes
AT peigao drugrepurposingfornonalcoholicfattyliverdiseasebyanalyzingnetworksamongdrugsdiseasesandgenes
AT naoakiono drugrepurposingfornonalcoholicfattyliverdiseasebyanalyzingnetworksamongdrugsdiseasesandgenes
AT shigehikokanaya drugrepurposingfornonalcoholicfattyliverdiseasebyanalyzingnetworksamongdrugsdiseasesandgenes